Cargando…

Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler

PURPOSE: The Respimat is a handheld, propellant-free, soft-mist inhaler. Observations by patients and physicians prompted development of an improved second-generation Respimat inhaler. Human-factor studies assessing the usability of the new inhaler and in vitro assessment of aerosol performance are...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhand, Rajiv, Eicher, Joachim, Hänsel, Michaela, Jost, Ingeborg, Meisenheimer, Martin, Wachtel, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407979/
https://www.ncbi.nlm.nih.gov/pubmed/30880941
http://dx.doi.org/10.2147/COPD.S190639
_version_ 1783401669873106944
author Dhand, Rajiv
Eicher, Joachim
Hänsel, Michaela
Jost, Ingeborg
Meisenheimer, Martin
Wachtel, Herbert
author_facet Dhand, Rajiv
Eicher, Joachim
Hänsel, Michaela
Jost, Ingeborg
Meisenheimer, Martin
Wachtel, Herbert
author_sort Dhand, Rajiv
collection PubMed
description PURPOSE: The Respimat is a handheld, propellant-free, soft-mist inhaler. Observations by patients and physicians prompted development of an improved second-generation Respimat inhaler. Human-factor studies assessing the usability of the new inhaler and in vitro assessment of aerosol performance are important to demonstrate functionality of the updated inhaler. METHODS: Studies were performed to assess any possible impact of the reusable Respimat inhaler design on aerosol performance (delivered dose [DD] and fine-particle dose [FPD]) and iteratively assess and improve usability of the new design. The tiotropium–olodaterol inhalation solution for Respimat was used as a model. The DD and FPD of the reusable Respimat inhaler (across multiple cartridges) and the disposable Respimat inhaler were determined by laser diffraction and with an alternative Andersen cascade impactor. Usability was measured across three studies involving health care professionals and patients with diagnoses of COPD, asthma, or combined disease (with and without experience with the Respimat inhaler). These studies measured performance of handling tasks and collected subjective feedback directly related to the inhaler’s new or altered features, which fed into optimization of the inhaler. RESULTS: DDs of tiotropium and olodaterol were stable up to 15 cartridges and consistently within the upper and lower limits of the disposable Respimat inhaler. The FPD was also found to be batch-consistent over the cartridges and comparable with the reference. The usability of the reusable Respimat inhaler compared with the disposable inhaler was improved in terms of assembly and daily use. Cartridge exchange was rated as intuitive and easy to very easy. CONCLUSION: The new reusable Respimat is a medical inhaler developed with enhanced features that meets health care professionals’ and patients’ needs. Drug delivery across multiple cartridges is not affected by the design. Compared with the original disposable inhaler, the usability of the reusable inhaler has been improved, and cartridge exchange was rated as easy to perform. The reusable Respimat provides greater convenience for patients vs the disposable inhaler, with reduced environmental impact.
format Online
Article
Text
id pubmed-6407979
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-64079792019-03-16 Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler Dhand, Rajiv Eicher, Joachim Hänsel, Michaela Jost, Ingeborg Meisenheimer, Martin Wachtel, Herbert Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: The Respimat is a handheld, propellant-free, soft-mist inhaler. Observations by patients and physicians prompted development of an improved second-generation Respimat inhaler. Human-factor studies assessing the usability of the new inhaler and in vitro assessment of aerosol performance are important to demonstrate functionality of the updated inhaler. METHODS: Studies were performed to assess any possible impact of the reusable Respimat inhaler design on aerosol performance (delivered dose [DD] and fine-particle dose [FPD]) and iteratively assess and improve usability of the new design. The tiotropium–olodaterol inhalation solution for Respimat was used as a model. The DD and FPD of the reusable Respimat inhaler (across multiple cartridges) and the disposable Respimat inhaler were determined by laser diffraction and with an alternative Andersen cascade impactor. Usability was measured across three studies involving health care professionals and patients with diagnoses of COPD, asthma, or combined disease (with and without experience with the Respimat inhaler). These studies measured performance of handling tasks and collected subjective feedback directly related to the inhaler’s new or altered features, which fed into optimization of the inhaler. RESULTS: DDs of tiotropium and olodaterol were stable up to 15 cartridges and consistently within the upper and lower limits of the disposable Respimat inhaler. The FPD was also found to be batch-consistent over the cartridges and comparable with the reference. The usability of the reusable Respimat inhaler compared with the disposable inhaler was improved in terms of assembly and daily use. Cartridge exchange was rated as intuitive and easy to very easy. CONCLUSION: The new reusable Respimat is a medical inhaler developed with enhanced features that meets health care professionals’ and patients’ needs. Drug delivery across multiple cartridges is not affected by the design. Compared with the original disposable inhaler, the usability of the reusable inhaler has been improved, and cartridge exchange was rated as easy to perform. The reusable Respimat provides greater convenience for patients vs the disposable inhaler, with reduced environmental impact. Dove Medical Press 2019-03-05 /pmc/articles/PMC6407979/ /pubmed/30880941 http://dx.doi.org/10.2147/COPD.S190639 Text en © 2019 Dhand et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Dhand, Rajiv
Eicher, Joachim
Hänsel, Michaela
Jost, Ingeborg
Meisenheimer, Martin
Wachtel, Herbert
Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
title Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
title_full Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
title_fullStr Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
title_full_unstemmed Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
title_short Improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable Respimat inhaler
title_sort improving usability and maintaining performance: human-factor and aerosol-performance studies evaluating the new reusable respimat inhaler
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6407979/
https://www.ncbi.nlm.nih.gov/pubmed/30880941
http://dx.doi.org/10.2147/COPD.S190639
work_keys_str_mv AT dhandrajiv improvingusabilityandmaintainingperformancehumanfactorandaerosolperformancestudiesevaluatingthenewreusablerespimatinhaler
AT eicherjoachim improvingusabilityandmaintainingperformancehumanfactorandaerosolperformancestudiesevaluatingthenewreusablerespimatinhaler
AT hanselmichaela improvingusabilityandmaintainingperformancehumanfactorandaerosolperformancestudiesevaluatingthenewreusablerespimatinhaler
AT jostingeborg improvingusabilityandmaintainingperformancehumanfactorandaerosolperformancestudiesevaluatingthenewreusablerespimatinhaler
AT meisenheimermartin improvingusabilityandmaintainingperformancehumanfactorandaerosolperformancestudiesevaluatingthenewreusablerespimatinhaler
AT wachtelherbert improvingusabilityandmaintainingperformancehumanfactorandaerosolperformancestudiesevaluatingthenewreusablerespimatinhaler